Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00625729 · OUTCOME

Number of Patients Exhibiting Natural Killer Cell Expansion

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia · Source last updated 2017-12-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Participants
Interval / dispersion
Not reported
Time frame
Day 14

What was measured

Successful natural killer (NK) cell expansion will be defined as an absolute circulating donor-derived NK cell count of \>100 cells/μl 14 days after infusion with \<5% donor T and B cells in the mononuclear population.

Groups in this outcome

Patients Treated With Natural Killer Cells

Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Patients Treated With Natural Killer Cells6

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Patients Treated With Natural Killer Cells0Not reportedNot reportedNot reportedNot reported
Complete source fields
anticipated Posting Date
2010-06
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    units
    Participants
description
Successful natural killer (NK) cell expansion will be defined as an absolute circulating donor-derived NK cell count of \>100 cells/μl 14 days after infusion with \<5% donor T and B cells in the mononuclear population.
groups
  1. description
    Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.
    id
    OG000
    title
    Patients Treated With Natural Killer Cells
param Type
NUMBER
reporting Status
POSTED
time Frame
Day 14
title
Number of Patients Exhibiting Natural Killer Cell Expansion
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice